POLYSTYRENELOOP
3.6.2021 19:01:08 CEST | Business Wire | Press release
A new recycling plant in the Netherlands will recycle expanded polystyrene (EPS) demolition waste and also handle a legacy additive.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210602005924/en/
The PolyStyreneLoop recycling plant in Terneuzen, Netherlands, is scheduled to open on the 16th of June. The plant was built to prove the technical and economic feasibility of a large-scale, closed-loop solution for the recycling of EPS waste.
The PolyStyreneLoop facility will recycle EPS insulation using a physical recycling process based on the CreaSolv® Technology. This technology will turn EPS foam demolition waste from building and construction insulation (B&C) from the Netherlands, Germany and other countries into new high quality raw material. All kinds of impurities, such as cement or other construction residues, as well as the legacy additive HBCD, will be safely removed and valuable bromine recovered.
“This plant showcases how the EPS industry is always looking for ways to boost its recycling capabilities,” said Lein Tange, Co-Director of PolyStyreneLoop. “The purpose of this plant is to pave the way for the construction of similar EPS recycling plants in the rest of Europe.”
The legal structure of the plant, which benefited from a European Union LIFE programme grant, was also unique. It has been built by the PolyStyreneLoop Cooperative, a Dutch non-profit organisation whose members comprise more than 70 industry representatives from the whole polystyrene foam value chain.
The Terneuzen plant will have the capacity to recycle 3,300 metric tonnes of polystyrene foam demolition waste coming from B&C per year, validating the technical, economic, and environmental viability of a new recycling process in which polystyrene foams containing HBCD can be fully integrated in the circular economy rather than being lost from circularity.
“It’s a real plus that the plant can not only take care of current recycling waste but also legacy recycling waste,” said Jan Noordegraaf, co-director of the plant. “Moreover, we can do this with about the same energy input as mechanical recycling and the energy we use comes solely from windmills.”
The PSLoop plant will demonstrate the possibility of infinite recycling of EPS B&C waste. Later, it will also recycle extruded polystyrene, or XPS, also known as StyrofoamTM .
EPS is a lightweight foam composed of 98% air and 2% technology with outstanding protective and thermal insulation properties. In addition to building and road construction uses, it is widely used in packaging to protect everything from heavy white goods to sensitive electronics, fresh fruit and vegetables, vaccines and even bees.
About PolyStyreneLoop
PolyStyreneLoop is a cooperative representing more than 70 companies from the polystyrene foam value chain. Its members include includes polystyrene raw material producers, foam manufacturers, additives suppliers, foam converters and recyclers as well as EUMEPS, the association and voice of European Manufacturers of Expanded Polystyrene.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210602005924/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
